Advance AI LLC, Maker of MedoraMD, Named an OpenAI Select Partner
The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact.
As an OpenAI Select Partner, Advance AI LLC will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations put GPT-6 Astra to work across more of their business, using deeper reasoning and computer use to complete complex workflows and deliver finished work. Advance AI focuses on AI workflows for specialty healthcare practices, with clinician review and sign-off on every AI draft.
"Being named an OpenAI Select Partner reflects our focus on deploying AI carefully in specialty healthcare, where clinicians stay in control of every output," said
Advance AI LLC supports organizations across healthcare, specifically allergy and immunology practices, with AI documentation workflow design, deployment and support. Its work includes building MedoraMD, an AI platform built together with a practicing allergy and immunology practice, where visit documentation and skin-test-panel documentation support clinician workflows under direct clinician review; every clinical AI output is a draft, confirmed and signed by the clinician.
Looking ahead, Advance AI LLC plans to expand its AI enablement work with specialty practices.
Learn more about the OpenAI Partner Network: https://openai.com/business/partners/
View original content to download multimedia:https://www.prnewswire.com/news-releases/advance-ai-llc-maker-of-medoramd-named-an-openai-select-partner-302913451.html
SOURCE AdvanceAI LLC
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Zhejiang Wenda Pharma Announces Positive Results from Phase II Trial of Oral BET Inhibitor NHWD-870 HCl at the 2026 ESMO Annual Meeting
- Cardano Price Prediction: ADA Holders Turn to Pepeto as Dijkstra Testnet Opens and Talk Grows
- DIRECTV Adds NHL's New Carolina Hurricanes, Columbus Blue Jackets, Minnesota Wild, and St. Louis Blues Regional Channels
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!





Tweet
Share